1. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD

2. Goals

3. Multiple Challenges in Statin Selection

4. Late-Breaking Clinical Trial Session at AHA 2017

5. REAL-CAD

6. Primary Endpoint (CV Death/MI/Ischemic Stroke/UA)

7. Secondary Composite Endpoint Primary Endpoint + Coronary Revascularization*

8. Additional Secondary Endpoints

9. Serial Changes in Lipid Parameters and hs-CRP

10. Safety Outcomes

11. Lower LDL-C Is Better: Is It Worth It?

12. Yes, It’s Worth It Further Proof That Lower Is Better

13. Recommendations for Lipid-Lowering Therapy in Patients With Established CAD

14. IMPROVE-IT: Benefit With Ezetimibe

15. J-PREDICT Primary Outcome: Cumulative Incidence of Diabetes

16. No Signal for T2D With Either 1- or 4-mg Dose of Pitavastatin

17. REAL-CAD: Application to Other Populations

18. Team: Nurses, Pharmacists, Nutritionists

19. Take-Home Pearls/Summary

20. Abbreviations

21. Abbreviations (cont)

22. Abbreviations (cont)